Get Adobe Flash player


Authors: Doroshenko A.M., Dybkova S.M., Rieznichenko L.S., Gruzina T.G., UlbergZ.R., Chekman I.S.

Pages: 292-299



According to the WHO data, iron deficiency anemia (IDA) is one of the most widespread pathological states as well as social problem. IDA is also one of the most important causes of intestinal dysbacteriosis. Varieties of oral iron preparations are widely prescribed as a part of medical care for patients with IDA. However, iron of existing oral antianemic drugs is not usually effectively absorbed. It may lead to elevation of intestinal iron content. The excess of iron in intestine can also result in dysbacteriosis. Moreover, existing antianemic drugs are not usually effective and safe. Thus, either IDA or oral iron supplementation may cause intestinal dysbacteriosis. Therefore, synthesis and development of new classes of biosafe and biocompatible antianemic drugs is an urgent task. Iron nanoparticles are promising in this direction. Due to high biological activity of iron nanoparticles, preclinical study of their effectiveness and safety for IDA treatment should include determining of their impact on intestinal microflora. The aim of this work was to study the influence of iron nanoparticles on intestinal microflora under conditions of oral administration to rats with IDA.

Substance of 40 nm sized spherical zero-valent iron nanoparticles (FeNPs) used in this study have been synthesized according to the original protocol of chemical condensation in water medium by iron (III) chloride reduction. We studied biological activity of FeNPs, as potential pharmacological substance with antianemic properties, on the model of IDA using Wistar female rats. IDA in experimental animals was modelled using iron deficiency diet. The experimental treatment course of rats with IDA included 10 days oral administration of FeNPs at/in therapeutic (12 mg/kg) dose. Commercial preparation based on pharmacological substance ferri (III) hydroxydi polymaltosum complexus was used as comparison drug in therapeutic dose. The status of microflora in lower part of rats’ gastrointestinal tract after experimental treatment course has been determined using standard microbiological protocols.

According to microbiological tests, rats fed with iron deficient diet demonstrated intestinal dysbiosis. In this case, there was a significant reduction of the protective microflora (bifidobacteria and lactobacilli). After 10 days of experimental treatment course (either with FeNPs or comparison drug), we observed normalization of quantitative parameters of protective and transient intestinal microorganisms in rats with IDA up to a level of healthy animals. However, recovery of number of sulphite-reductive clostridia in anemic animals’ gut, which had been receiving FeNPs, was more effective than in the case of comparison drug administration. FeNPs are possessed by favourable effect on the gastrointestinal tract microflora in case of IDA. Therefore, FeNPs are perspective as biosafe and biocompatible pharmacological substance for development of new class antianemic preparations.

Key words: iron nanoparticles, anemia, iron deficiency, dysbacteriosis, intestinal microflora, normalization.

This email address is being protected from spambots. You need JavaScript enabled to view it. 

The full text

In progress



  1. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med. 2003;163(12):1400–1404.
  2. Tompkins GR, O'Dell NL, Bryson IT, Pennington CB. The effects of dietary ferric iron and iron deprivation on the bacterial composition of the mouse intestine. Curr Microbiol. 2001;43(1):38–42.
  3. Balamurugan R, Mary RR, Chittaranjan S, Jancy H, Shobana Devi R, Ramakrishna BS. Low levels of faecal lactobacilli in women with iron-deficiency anaemia in south India. Br J Nutr. 2010;104(7):931–934.
  4. Dostal A, Chassard C, Hilty FM, Zimmermann MB, Jaeggi T, Rossi S, Lacroix C. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats. J Nutr. 2012;142(2):271–277.
  5. Dostal A, Fehlbaum S, Chassard C, Zimmermann MB, Lacroix C. Low iron availability in continuous in vitro colonic fermentations induces strong dysbiosis of the child gut microbial consortium and a decrease of main metabolites. FEMS Microbiol Ecol. 2013;83(1):161–175.
  6. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–119.
  7. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol. 2008;16(3):107–114.
  8. Andrews SC, Robinson AK, Rodriguez-Quinones F. Bacterial iron homeostasis. FEMS Microbiol Rev. 2003;27(2–3):215–237.
  9. Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Scientific World Journal. 2012;2012:846824.
  10. Zimmermann MB, Chassard C, Rohner F, N'goran EK, Nindjin C, Dostal A, Utzinger J, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr. 2010;92(6):1406–1415.
  11. Mevissen-Verhage EA, Marcelis JH, Harmsen-Van Amerongen WC, de Vos NM, Verhoef J. Effect of iron on neonatal gut flora during the first three months of life. Eur J Clin Microbiol. 1985;4(3):273–278.
  12. Lee SH, Shinde P, Choi J, Park M, Ohh S, Kwon IK, Pak SI, Chae BJ. Effects of dietary iron levels on growth performance, hematological status, liver mineral concentration, fecal microflora, and diarrhea incidence in weanling pigs. Biol Trace Elem Res. 2008;126(1)S57–68.
  13. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1):12–33.
  14. Chekman IS. Nanofarmakologiia [Nanopharmacology]. Kyiv: Zadruha Publ., 2011. 424 p.
  15. Chekman IS, Ulberg ZR, Malanchuk VO, Gorchakova NO, Zupanets IO. Nanonauka, nanobiologiia, nanofarmatsiia [Nanoscience, nanobiology, nanopharmacy]. Kyiv: Poligraf plius Publ., 2012. 328 p.
  16. Rieznichenko LS, Dybkova SM, Doroshenko AM, Chekman IS, Ulberg ZR. [Synthesis of iron nanoparticles and characterization of their biosafety]. Visnyk Problem Biologii i Medytsyny. 2014;2(3):319–324.
  17. Guidelines “Safety assessment of medical nanopreparations” approved by the Scientific Expert Council of the State Expert Centre of the Ministry of Health of Ukraine (protocol 8, dated
  18. Stefanov O, editors.Doklinichni doslidzhennia likarskykh zasobiv (metodychni rekomendatsii) [Preclinical studies of drugs (Guidelines)]. Kyiv: Avitsenna Publ., 2002. 527 p.
  19. Labinskaia AS. Mikrobiologiia s tekhnikoi mikrobiologicheskikh issledovanii [Microbiology with technique of microbiological studies]. Moscow: Meditsina Publ., 1978. 394 p.

Lakin GF. Biometriia: uchebnoe posobie dlia biologicheskikh spetsialnostei VUZov [Biometrics: a training manual for biological specialties of universities]. Moscow: Vysshaia Shkola Publ., 1990. 352 p.